Use of liposomal anthracyclines in Kaposi's sarcoma Journal Article
| Authors: | Krown, S. E.; Northfelt, D. W.; Osoba, D.; Stewart, J. S. |
| Article Title: | Use of liposomal anthracyclines in Kaposi's sarcoma |
| Abstract: | Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV. © 2004 Elsevier Inc. All rights reserved. |
| Keywords: | cancer survival; thalidomide; clinical trial; drug tolerability; fatigue; histopathology; neutropenia; pathogenesis; review; doxorubicin; diarrhea; drug efficacy; drug safety; hypertension; nonhuman; side effect; skin toxicity; drug approval; paclitaxel; cancer staging; neurotoxicity; cell proliferation; unindexed drug; quality of life; drug eruption; liver toxicity; lung toxicity; anemia; etoposide; leukopenia; mucosa inflammation; nausea; neuropathy; stomatitis; thrombocytopenia; antineoplastic combined chemotherapy protocols; vincristine; antineoplastic activity; food and drug administration; vinblastine; docetaxel; abdominal pain; backache; drug hypersensitivity; dyspnea; fever; flushing; hypotension; lung metastasis; cancer regression; rigor; thorax pain; drug distribution; drug uptake; heart failure; cardiotoxicity; drug response; mitoxantrone; daunorubicin; semaxanib; erythema; bleomycin; nausea and vomiting; epirubicin; liver disease; acquired immune deficiency syndrome; flu like syndrome; headache; vinca alkaloid; alitretinoin; antiretrovirus agent; kaposi sarcoma; sarcoma, kaposi; taxane derivative; antibiotics, antineoplastic; anthracycline; hand foot syndrome; bacterial infection; alopecia; photodynamic therapy; proteinase inhibitor; retinoid; clinical trials; tachycardia; liposome; liposomes; encapsulation; granulocytopenia; bone marrow toxicity; human herpesvirus 8; chorionic gonadotropin; zidovudine; fumagillol chloroacetylcarbamate; cryotherapy; hair loss; matrix metalloproteinase inhibitor; recombinant alpha2a interferon; recombinant alpha2b interferon; colony stimulating factor; didanosine; sclerosing agent; argon laser; humans; human; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 31 |
| Issue: | Suppl.13 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-12-01 |
| Start Page: | 36 |
| End Page: | 52 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2004.08.003 |
| PROVIDER: | scopus |
| PUBMED: | 15717737 |
| DOI/URL: | |
| Notes: | Semin. Oncol. -- Cited By (since 1996):70 -- Export Date: 16 June 2014 -- CODEN: SOLGA -- Source: Scopus |
